JP2014500316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500316A5 JP2014500316A5 JP2013546126A JP2013546126A JP2014500316A5 JP 2014500316 A5 JP2014500316 A5 JP 2014500316A5 JP 2013546126 A JP2013546126 A JP 2013546126A JP 2013546126 A JP2013546126 A JP 2013546126A JP 2014500316 A5 JP2014500316 A5 JP 2014500316A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- compound
- methyl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 201000009273 Endometriosis Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 208000005641 Adenomyosis Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 4
- 201000009274 endometriosis of uterus Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 201000010260 leiomyoma Diseases 0.000 claims description 4
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 229940044959 vaginal cream Drugs 0.000 claims description 2
- 239000000522 vaginal cream Substances 0.000 claims description 2
- 229940044950 vaginal gel Drugs 0.000 claims description 2
- 239000000029 vaginal gel Substances 0.000 claims description 2
- 229940120293 vaginal suppository Drugs 0.000 claims description 2
- 239000006216 vaginal suppository Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 201000002595 endometriosis of ovary Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000030747 ovarian endometriosis Diseases 0.000 description 2
- 0 *CC([C@@](*)(CC1)C(*)(CC2c3ccccc3)C1C(CC1)C2=C(CC2)C1=CC2=*)=O Chemical compound *CC([C@@](*)(CC1)C(*)(CC2c3ccccc3)C1C(CC1)C2=C(CC2)C1=CC2=*)=O 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/062068 WO2011119194A1 (en) | 2010-03-22 | 2010-12-23 | Compositions and methods for non-toxic delivery of antiprogestins |
| USPCT/US2010/062068 | 2010-12-23 | ||
| PCT/US2011/050859 WO2012087389A1 (en) | 2010-12-23 | 2011-09-08 | Novel 19-nor-steroids and their use for treating progesterone-dependent conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016135644A Division JP2016180004A (ja) | 2010-12-23 | 2016-07-08 | プロゲステロン依存性状態を治療するための新規１９−ノルステロイドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014500316A JP2014500316A (ja) | 2014-01-09 |
| JP2014500316A5 true JP2014500316A5 (cg-RX-API-DMAC7.html) | 2014-10-09 |
Family
ID=44681424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546126A Withdrawn JP2014500316A (ja) | 2010-12-23 | 2011-09-08 | プロゲステロン依存性状態を治療するための新規１９−ノルステロイドおよびその使用方法 |
| JP2016135644A Pending JP2016180004A (ja) | 2010-12-23 | 2016-07-08 | プロゲステロン依存性状態を治療するための新規１９−ノルステロイドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016135644A Pending JP2016180004A (ja) | 2010-12-23 | 2016-07-08 | プロゲステロン依存性状態を治療するための新規１９−ノルステロイドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130274234A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2655394A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014500316A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130132955A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103403017A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011345341B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2820877A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013006732A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ612295A (cg-RX-API-DMAC7.html) |
| SG (1) | SG191207A1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA113283C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012087389A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201304381B (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX363640B (es) | 2012-05-31 | 2019-03-28 | Repros Therapeutics Inc | Formulaciones y metodos para la administracion vaginal de antiprogestinas. |
| US9545411B2 (en) * | 2012-11-02 | 2017-01-17 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| MX384159B (es) * | 2014-05-05 | 2025-03-14 | Repros Therapeutics Inc | Formulaciones y métodos para el suministro vaginal de antiprogestinas. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2573657B1 (fr) * | 1984-11-29 | 1989-05-12 | Roussel Uclaf | Produit comprenant une substance antiprogestomimetique et une substance uterotonique |
| US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| EP0900234B1 (en) * | 1996-05-01 | 2000-07-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 21-substituted progesterone derivatives as new antiprogestational agents |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| CA2403756C (en) * | 2000-03-17 | 2010-02-09 | Hyun K. Kim | Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| CA2673128C (en) * | 2006-10-24 | 2018-07-03 | Repros Therapeutics Inc. | Compositions and methods for suppressing endometrial proliferation |
| US20090118253A1 (en) * | 2007-11-05 | 2009-05-07 | Repros Therapeutics Inc. | Compositions and methods for treating dysfunctional uterine bleeding |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| TWI539953B (zh) * | 2008-04-28 | 2016-07-01 | 瑞波若斯治療學公司 | 用於治療乳癌之組成物和方法 |
-
2011
- 2011-08-09 UA UAA201309244A patent/UA113283C2/uk unknown
- 2011-09-08 WO PCT/US2011/050859 patent/WO2012087389A1/en not_active Ceased
- 2011-09-08 KR KR1020137019568A patent/KR20130132955A/ko not_active Ceased
- 2011-09-08 CN CN2011800682607A patent/CN103403017A/zh active Pending
- 2011-09-08 MX MX2013006732A patent/MX2013006732A/es unknown
- 2011-09-08 CA CA2820877A patent/CA2820877A1/en not_active Abandoned
- 2011-09-08 EP EP11761438.8A patent/EP2655394A1/en not_active Withdrawn
- 2011-09-08 NZ NZ612295A patent/NZ612295A/en not_active IP Right Cessation
- 2011-09-08 AU AU2011345341A patent/AU2011345341B2/en not_active Ceased
- 2011-09-08 US US13/997,097 patent/US20130274234A1/en not_active Abandoned
- 2011-09-08 SG SG2013046602A patent/SG191207A1/en unknown
- 2011-09-08 JP JP2013546126A patent/JP2014500316A/ja not_active Withdrawn
-
2013
- 2013-06-13 ZA ZA2013/04381A patent/ZA201304381B/en unknown
-
2016
- 2016-07-08 JP JP2016135644A patent/JP2016180004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2701400T3 (es) | Formulaciones para la administración vaginal de antiprogestinas | |
| JP2011518845A5 (cg-RX-API-DMAC7.html) | ||
| JP2008512426A5 (cg-RX-API-DMAC7.html) | ||
| JP2010510210A5 (cg-RX-API-DMAC7.html) | ||
| JP2010507685A5 (cg-RX-API-DMAC7.html) | ||
| TW200403065A (en) | New etonogestrel esters | |
| US20200222315A1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| JP2013522361A5 (cg-RX-API-DMAC7.html) | ||
| JP2014500316A5 (cg-RX-API-DMAC7.html) | ||
| AU2016200575B2 (en) | Compositions And Methods For Non-Toxic Delivery Of Antiprogestins | |
| CN1291990A (zh) | S－取代的11β－苯甲醛肟－雌－4,9－二烯一硫烃酸酯、其制备方法以及包含这些化合物的药物制剂 | |
| JP4837858B2 (ja) | 拮抗ホルモン特性を有する、１７β−アシル−１７α−プロピニル−１１β−（環状アミノ）アリールステロイド及びその誘導体 | |
| JP2017514851A5 (cg-RX-API-DMAC7.html) | ||
| JP2016180004A (ja) | プロゲステロン依存性状態を治療するための新規１９−ノルステロイドおよびその使用方法 | |
| JP4002438B2 (ja) | ステロイド類、それらの調製、それらの薬学的組成物およびこの化合物の使用 | |
| ES2708351T3 (es) | Forma de dosificación de un antagonista del receptor de progesterona | |
| Lin et al. | An adenomyomatous polyp presenting as a large hypervascular tumor and its response to a gonadotropin-releasing hormone agonist | |
| WO2017010515A1 (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニスト及びこれを用いた婦人科疾患治療剤 | |
| JP2004520411A5 (cg-RX-API-DMAC7.html) | ||
| KR20100037593A (ko) | 선택적으로 활성인 에스트로겐으로서의 8-베타-치환된 에스트라트리엔 | |
| Xu et al. | Metastable Form D of mifepristone: single crystal structure, similar lattice energy and enhanced pharmacodynamics | |
| ES2305210T3 (es) | Uso de antagonistas selectivos del er-beta como contraceptivos. | |
| JP2020114805A (ja) | エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び／又は器質的病変の治療剤 | |
| JP2009512633A5 (cg-RX-API-DMAC7.html) | ||
| HK1206622B (zh) | 经阴道递送抗孕素的调配物和方法 |